

1. NAME OF THE MEDICINAL PRODUCT

Cataflam 50 mg Tablets.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Diclofenac potassium.....50mg

For a full list of excipients, see section 6.1

3. PHARMACEUTICAL FORM

One Cataflam tablet contains 50 mg of diclofenac potassium.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Treatment of:

- Post-traumatic pain, inflammation and swelling, e.g., due to sprains .
- Post-operative pain, inflammation and swelling, e.g., following dental or orthopedic surgery • Painful and/or inflammatory conditions in gynecology, e.g., primary dysmenorrhea or adnexitis .
- Migraine attacks.
- Painful syndromes of the vertebral column.
- Non-articular rheumatism.
- As an adjuvant in severe painful inflammatory infections of the ear, nose or throat, e.g., pharyngotonsillitis, otitis. In keeping with general therapeutic principles, the underlying disease should be treated with basic therapy, as appropriate. Fever alone is not an indication.

4.2 Posology and method of administration

Dosage regimen

As a general recommendation, the dose should be individually adjusted. Adverse effects may be minimized by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 6 Warnings and precautions).

General target population

The recommended initial daily dose is 100 to 150 mg. In milder cases, 75 to 100 mg daily is usually sufficient.

The total daily dose should generally be divided into 2 or 3 separate doses, as applicable.

In primary dysmenorrhea, the daily dose should be individually adjusted and is generally 50 to 150 mg. An initial dose of 50 mg is usually sufficient. If necessary, an initial dose of 100 mg can be prescribed with a maximum of 200 mg/day reached over the course of several menstrual cycles. Treatment should be started on appearance of the first symptoms and, depending on the symptomatology, continued for a few days.

In migraine, an initial dose of 50 mg should be taken at the first signs of an impending attack. In cases where pain relief within 2 hours after the first dose is not sufficient, a further dose of 50 mg may be taken. If needed, further doses of 50 mg may be taken at intervals of 4 to 6 hours, not exceeding a total dose of 200 mg per day

Renal impairment

Cataflam is contraindicated in patients with renal failure (GFR <15 mL/min/1.73 m²)

No specific studies have been carried out in patients with renal impairment, therefore, no specific dose adjustment recommendations can be made. Caution is advised when administering Cataflam to patients with renal impairment (see section 6 Warnings and precautions)

Hepatic impairment

Cataflam is contraindicated in patients with hepatic failure (see section 5 Contraindications).

No specific studies have been carried out in patients with hepatic impairment, therefore, no specific dose adjustment recommendations can be made. Caution is advised when administering Cataflam to patients with mild to moderate hepatic impairment.

Pediatric patients (below 18 years)

Cataflam tablets are not recommended for use in children and adolescents below 14 years of age. For treatment in children and adolescents below 14 years of age, oral drops or suppositories of diclofenac 12.5 mg and 25 mg could be used. For adolescents aged 14 years and over, a daily dose of 75 to 100 mg is usually sufficient. The maximum daily dose of 150 mg should not be exceeded. The total daily dose should generally be divided into 2 to 3 separate doses, as applicable.

The use of Cataflam (all forms) in migraine attacks has not been established in children and adolescents

Established cardiovascular disease or significant cardiovascular risk factors

Treatment with Cataflam is generally not recommended in patients with established cardiovascular disease or uncontrolled hypertension. If needed, patients with established cardiovascular disease, uncontrolled hypertension or significant risk factors for cardiovascular disease should be treated with Cataflam only after careful consideration and only at doses ≤100 mg daily when treatment continues for more than 4 weeks.

Method of administration

The tablets should be swallowed whole with liquid, preferably before meals, and must not be divided or chewed.

4.3 Contraindications

- Known hypersensitivity to the active substance, sodium metabisulphite (***solution for injection only***) or any of the other excipients.
- Active gastric or intestinal ulcer, bleeding or perforation
- Last trimester of pregnancy (see section 9 Pregnancy, lactation, females and males of reproductive potential) .
- Hepatic failure.
- Renal failure (GFR <15 mL/min/1.73 m²)
- Severe cardiac failure (see section 6 Warnings and precautions)
- Like other non-steroidal anti-inflammatory drugs (NSAIDs), Cataflam is also contraindicated in patients in whom the use of acetylsalicylic acid or other NSAIDs can precipitate asthma, angioedema, urticaria, or acute rhinitis (i.e., NSAID-induced cross-reactivity reactions)

4.4 Special warnings and special precautions for use

Gastrointestinal effects

Gastrointestinal bleeding, ulceration or perforation, which can be fatal, have been reported with all NSAIDs, including diclofenac, and may occur at any time during treatment, with or without warning symptoms or a previous history of serious gastrointestinal events. They generally have more serious consequences in the elderly. If gastrointestinal bleeding or ulceration occurs in patients receiving Cataflam, the treatment should be discontinued.

As with all NSAIDs, including diclofenac, close medical surveillance is imperative and particular caution should be exercised when prescribing Cataflam in patients with symptoms indicative of gastrointestinal (GI) disorders or with a history suggestive of gastric or intestinal ulceration, bleeding or perforation (see section 7 Adverse drug reactions). The risk of GI bleeding is higher with increasing NSAID doses and in patients with a history of ulcer, particularly if complicated with hemorrhage or perforation and in the elderly.

To reduce the risk of GI toxicity in patients with a history of ulcer, particularly if complicated with hemorrhage or perforation, and in the elderly, the treatment should be initiated and maintained at the lowest effective dose.

Combination therapy with protective agents (e.g. proton pump inhibitors or misoprostol) should be considered for these patients, and also for patients requiring concomitant use of low-dose acetylsalicylic acid (ASA) or other drugs likely to increase gastrointestinal risk. Patients with a history of GI toxicity, particularly the elderly, should report any unusual abdominal symptoms (especially GI bleeding). Caution is recommended in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as systemic corticosteroids, anticoagulants, antiplatelet agents or selective serotonin-reuptake inhibitors (see section 8 Interactions).

Close medical surveillance and caution should also be exercised in patients with ulcerative colitis or Crohn's disease, as their condition may be exacerbated.

NSAIDs, including diclofenac, may be associated with increased risk of gastro-intestinal anastomotic leak. Close medical surveillance and caution are recommended when using Cataflam after gastrointestinal surgery.

Cardiovascular effects

Treatment with NSAIDs including diclofenac, particularly at high dose and in long term, may be associated with a small increased risk of serious cardiovascular thrombotic events (including myocardial infarction and stroke).

Treatment with Cataflam is generally not recommended in patients with established cardiovascular disease (congestive heart failure, established ischemic heart disease, peripheral arterial disease) or uncontrolled hypertension. If needed, patients with established cardiovascular disease, uncontrolled hypertension or significant risk factors for cardiovascular disease (e.g., hypertension, hyperlipidemia, diabetes mellitus and smoking) should be treated with Cataflam only after careful consideration and only at doses ≤ 100 mg daily when treatment continues for more than 4 weeks.

As the cardiovascular risks of diclofenac may increase with dose and duration of exposure, the lowest effective daily dose should be used for the shortest duration possible. The patient's need for symptomatic relief and response to therapy should be re-evaluated periodically, especially when treatment continues for more than 4 weeks. Patients should remain alert for the signs and symptoms of serious arteriothrombotic events (e.g., chest pain, shortness of breath, weakness, slurring of speech), which can occur without warnings. Patients should be instructed to see a physician immediately in case of such an event.

Hematologic effects

Use of Cataflam is recommended only for short-term treatment. If, however, Cataflam is used for a prolonged period, monitoring of the blood count is recommended, as with other NSAIDs.

Like other NSAIDs, diclofenac may temporarily inhibit platelet aggregation. Patients with defects of hemostasis should be carefully monitored.

Respiratory effects (pre-existing asthma)

In patients with asthma, seasonal allergic rhinitis, swelling of the nasal mucosa (i.e., nasal polyps), chronic obstructive pulmonary diseases or chronic infections of the respiratory tract (especially if linked to allergic rhinitis-like symptoms), reactions on NSAIDs like asthma exacerbations (so-called intolerance to analgesics/analgesics-asthma), Quincke's edema or urticaria are more frequent than in other patients. Therefore, special caution is recommended in such patients (readiness for emergency). This is applicable as well for patients who are allergic to other substances, e.g., with skin reactions, pruritus or urticaria.

Hepatobiliary effects

Close medical surveillance is required when prescribing Cataflam to patients with impaired hepatic function, as their condition may be exacerbated.

As with other NSAIDs, including diclofenac, values of one or more liver enzymes may increase. During prolonged treatment with Cataflam, regular monitoring of hepatic function is indicated as a precautionary measure. If abnormal liver function tests persist or worsen, if clinical signs or symptoms consistent with liver disease develop, or if other

manifestations occur (e.g., eosinophilia, rash), Cataflam should be discontinued. Hepatitis may occur with use of diclofenac without prodromal symptoms.

Caution is called for when using Cataflam in patients with hepatic porphyria, since it may trigger an attack .

Skin reactions

Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs, including Cataflam (see section 7 Adverse drug reactions). Patients appear to be at highest risk of these reactions early in the course of therapy, the onset of the reaction occurring in the majority of cases within the first month of treatment. Cataflam should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity.

As with other NSAIDs, allergic reactions, including anaphylactic/anaphylactoid reactions, can also occur in rare cases with diclofenac without earlier exposure to the drug.

Renal effects

As fluid retention and edema have been reported in association with NSAID therapy, including diclofenac, particular caution is called for in patients with impaired cardiac or renal function, history of hypertension, the elderly, patients receiving concomitant treatment with diuretics or medicinal products that can significantly impact renal function, and in those patients with substantial extracellular volume depletion from any cause, e.g., before or after major surgery (see section 5 Contraindications). Monitoring of renal function is recommended as a precautionary measure when using Cataflam in such cases. Discontinuation of therapy is usually followed by recovery to the pre-treatment state.

Geriatric patients

Caution is indicated in the elderly on basic medical grounds, especially in frail elderly patients or those with a low body weight.

Interactions with NSAIDs

The concomitant use of Cataflam with systemic NSAIDs including cyclooxygenase-2 selective inhibitors, should be avoided due to the potential for additive undesirable effects

Masking signs of infections

Like other NSAIDs, diclofenac may mask the signs and symptoms of infection due to its pharmacodynamic properties.

4.5 Interaction with other medicinal products and other forms of interaction

The following interactions include those observed with Cataflam oral suspension and/or other pharmaceutical forms of diclofenac.

Observed interactions to be considered

CYP2C9 inhibitors: Caution is recommended when co-prescribing diclofenac with CYP2C9 inhibitors (such as voriconazole), which could result

in a significant increase in peak plasma concentrations and exposure to diclofenac.

Lithium: If used concomitantly, diclofenac may raise plasma concentrations of lithium. Monitoring of the serum lithium level is recommended.

Digoxin: If used concomitantly, diclofenac may raise plasma concentrations of digoxin. Monitoring of the serum digoxin level is recommended.

Diuretics and antihypertensive agents: Like other NSAIDs, concomitant use of diclofenac with diuretics or antihypertensive agents (e.g., beta-blockers, angiotensin converting enzyme (ACE) inhibitors) may cause a decrease in their antihypertensive effect. Therefore, the combination should be administered with caution and patients, especially the elderly, should have their blood pressure periodically monitored. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy and periodically thereafter, particularly for diuretics and ACE inhibitors due to the increased risk of nephrotoxicity.

Ciclosporin and tacrolimus: Diclofenac, like other NSAIDs, may increase the nephrotoxicity of ciclosporin and tacrolimus, due to the effect on renal prostaglandins. Therefore, it should be given at doses lower than those that would be used in patients not receiving ciclosporin or tacrolimus.

Drugs known to cause hyperkalemia: Concomitant treatment with potassium-sparing diuretics, ciclosporin, tacrolimus or trimethoprim may be associated with increased serum potassium levels, which should therefore be monitored frequently

Quinolone antibacterials: There have been isolated reports of convulsions which may have been due to concomitant use of quinolones and NSAIDs.

Anticipated interactions to be considered

Other NSAIDs and corticosteroids: Concomitant administration of diclofenac and other systemic NSAIDs or corticosteroids may increase the frequency of gastrointestinal undesirable effects

Anticoagulants and anti-platelet agents: Caution is recommended since concomitant administration could increase the risk of bleeding. Although clinical investigations do not appear to indicate that diclofenac affects the action of anticoagulants, there are reports of an increased risk of hemorrhage in patients receiving diclofenac and anticoagulants concomitantly. Close monitoring of such patients is recommended.

Selective serotonin reuptake inhibitors (SSRIs): Concomitant administration of systemic NSAIDs, including diclofenac, and SSRIs may increase the risk of gastrointestinal bleeding

Antidiabetics: Clinical studies have shown that diclofenac can be given together with oral antidiabetic agents without influencing their clinical effect. However, there have been isolated reports of both hypoglycaemic and hyperglycaemic effects necessitating changes in the dosage of the antidiabetic agents during treatment with diclofenac. For this reason, monitoring of the blood glucose level is recommended as a precautionary measure during concomitant therapy. There have also been isolated reports

of metabolic acidosis when diclofenac was co-administered with metformin, especially in patients with pre-existing renal impairment.

Phenytoin: When using phenytoin concomitantly with diclofenac, monitoring of phenytoin plasma concentrations is recommended due to an expected increase in exposure to phenytoin.

Methotrexate: Caution is recommended when NSAIDs, including diclofenac, are administered less than 24 hours before or after treatment with methotrexate, since blood concentrations of methotrexate may rise and the toxicity of this substance be increased.

CYP2C9 inducers: Caution is recommended when co-prescribing diclofenac with CYP2C9 inducers (such as rifampicin), which could result in a significant decrease in plasma concentration and exposure to diclofenac.

4.6 Pregnancy and lactation

Pregnancy

There are insufficient data on the use of diclofenac in pregnant women. Some epidemiological studies suggest an increased risk of miscarriage after use of prostaglandin synthesis inhibitor (such as NSAIDs) in early pregnancy, however the overall data are inconclusive. Diclofenac has been shown to cross the placental barrier in humans. Use of NSAIDs, including diclofenac, can cause uterine inertia, premature closure of the fetal ductus arteriosus and fetal renal impairment leading to

oligohydramnios. -Because of these risks, Cataflam should not be used during the first two trimesters of pregnancy unless the expected benefits to the mother outweigh the risks to the foetus. In addition, Cataflam should not be used during the third trimester of pregnancy

In animal reproduction studies, no evidence of teratogenicity was observed in mice, rats, or rabbits given diclofenac daily during the period of organogenesis at doses up to approximately 0.41, 0.41, and 0.81 times, respectively, the maximum recommended human dose (MRHD) of Cataflam, despite the presence of maternal and fetal toxicity (see Animal data).

Breast-feeding

Like other NSAIDs, diclofenac passes into the breast milk in small amounts. Therefore, Cataflam should not be administered during breast feeding in order to avoid undesirable effects in the infant.

Females and males of reproductive potential

Female fertility

As with other NSAIDs, the use of Cataflam may impair female fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of Cataflam should be considered.

Male fertility

There is no human data on the effect of Cataflam on male fertility. Diclofenac administered to male and female rats at 4 mg/kg/day (approximately 0.16 times the MRHD based on BSA comparison) did not affect fertility.

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines been performed

4.8 Undesirable effects

Adverse drug reactions

Adverse drug reactions from clinical trials and/or spontaneous or literature reports (Table 41) are listed by MedDRA system organ class. Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention (CIOMS III): very common ($>1/10$); common ($\geq 1/100$ to $<1/10$); uncommon ($\geq 1/1,000$ to $<1/100$); rare ($\geq 1/10,000$ to $<1/1,000$); very rare ($<1/10,000$).

The following undesirable effects include those reported with Cataflam oral suspension and/or other pharmaceutical forms of diclofenac, with either short-term or long-term use.

Table 4-1 Adverse drug reactions

Blood and lymphatic system disorders	
Very rare:	Thrombocytopenia, leukopenia, anemia (including hemolytic and aplastic anemia), agranulocytosis.
Immune system disorders	
Rare:	Hypersensitivity, anaphylactic and anaphylactoid reactions (including hypotension and shock).
Very rare:	Angioedema (including face edema).
Psychiatric disorders	
Very rare:	Disorientation, depression, insomnia, nightmare, irritability, psychotic disorder.
Nervous system disorders	
Common:	Headache, dizziness.
Rare:	Somnolence.
Very rare:	Paresthesia, memory impairment, convulsion, anxiety, tremor, aseptic meningitis, dysgeusia, cerebrovascular accident.
Eye disorders	
Very rare:	Visual impairment, blurred vision, diplopia.
Ear and labyrinth disorders	
Common:	Vertigo.
Very rare:	Tinnitus, impaired hearing
Cardiac disorders	
Uncommon *:	Myocardial infarction, cardiac failure, palpitations, chest pain.
Frequency not known	Kounis syndrome
Vascular disorders	
Very rare:	Hypertension, Vasculitis.

Respiratory, thoracic and mediastinal disorders

Rare:	Asthma (including dyspnea).
Very rare:	Pneumonitis.

Gastrointestinal disorders

Common:	Nausea, vomiting, diarrhea, dyspepsia, abdominal pain, flatulence, decreased appetite.
Rare:	Gastritis, gastrointestinal hemorrhage, hematemesis, hemorrhagic diarrhea, melena, gastrointestinal ulcer (with or without bleeding, gastrointestinal stenosis, or perforation, which may lead to peritonitis).
Very rare:	Colitis (including hemorrhagic colitis, ischemic colitis and exacerbation of ulcerative colitis or Crohn's disease), constipation, stomatitis, glossitis, esophageal disorder, intestinal diaphragm disease, pancreatitis.

Hepatobiliary disorders

Common:	Transaminases increased.
Rare:	Hepatitis, jaundice, liver disorder.
Very rare:	Fulminant hepatitis, hepatic necrosis, hepatic failure.

Skin and subcutaneous disorders

tissue	Rash.
Common:	
Rare:	Urticaria.
Very rare:	Bullous dermatitis, eczema, erythema, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell's syndrome), exfoliative dermatitis, alopecia, photosensitivity reaction, purpura, Henoch-Schoenlein purpura, pruritus.

Renal and urinary disorders

Very rare:	Acute kidney injury (acute renal failure), hematuria, proteinuria, nephrotic syndrome, tubulointerstitial nephritis, renal papillary necrosis.
------------	--

General disorders and administration site conditions

Rare:	Edema.
-------	--------

*The frequency reflects data from long-term treatment with a high dose (150 mg daily).

Description of selected adverse drug reactions Arteriothrombotic events

Meta-analysis and pharmacoepidemiological data point towards a small increased risk of arteriothrombotic events (for example myocardial infarction) associated with the use of diclofenac, particularly at a high dose (150 mg daily) and during long-term treatment **Visual effects**

Visual disturbances such as visual impairment, blurred vision or diplopia appear to be NSAID class effects and are usually reversible on

discontinuation. A likely mechanism for the visual disturbances is the inhibition of prostaglandin synthesis and other related compounds that alter the regulation of retinal blood flow resulting in potential changes in vision. If such symptoms occur during diclofenac treatment, an ophthalmological examination may be considered to exclude other causes.

4.9 Overdose

There is no typical clinical picture resulting from diclofenac overdosage. Overdosage can cause symptoms such as vomiting, gastrointestinal hemorrhage, diarrhea, dizziness, tinnitus or convulsions. In the event of significant poisoning, acute renal failure and liver damage are possible.

Therapeutic measures

Management of acute poisoning with NSAIDs, including diclofenac, essentially consists of supportive measures and symptomatic treatment. Supportive measures and symptomatic treatment should be given for complications such as hypotension, renal failure, convulsions, gastrointestinal disorder, and respiratory depression. Special measures such as forced diuresis, dialysis or hemoperfusion are probably of no help in eliminating NSAIDs, including diclofenac, due to the high protein binding and extensive metabolism.

Activated charcoal may be considered after ingestion of a potentially toxic overdose, and gastric decontamination (e.g. vomiting, gastric lavage) after ingestion of a potentially life-threatening overdose.

5 PHARMACOLOGICAL PROPERTIES

5.1. Pharmacodynamic properties

Mechanism of action (MOA)

Cataflam contains diclofenac potassium, a non-steroidal compound with pronounced antirheumatic, analgesic, anti-inflammatory, and antipyretic properties. Inhibition of prostaglandin biosynthesis, which has been demonstrated in experiments, is considered fundamental to its mechanism of action. Prostaglandins play an important role in causing inflammation, pain, and fever.

Cataflam tablets and capsules have a rapid onset of action which makes them particularly suitable for the treatment of acute painful and inflammatory conditions (**SCT and SC only**). Diclofenac *in vitro* does not suppress proteoglycan biosynthesis in cartilage at concentrations equivalent to the concentrations reached in humans.

5.2 Pharmacokinetics (PK) Properties

Absorption

Diclofenac is rapidly and completely absorbed from diclofenac potassium tablets. The absorption sets in immediately after administration and the same amount is absorbed as from an equivalent dose of diclofenac sodium gastro-resistant tablets.

Mean peak plasma concentrations of 3.8 micro mol/L are attained after 20 to 60 minutes after ingestion of one tablet of 50 mg. Pharmacokinetic behaviour does not change after repeated administration. No accumulation occurs provided the recommended dosage intervals are observed

Distribution

99.7% of diclofenac binds to serum proteins, mainly to albumin (99.4%). The apparent volume of distribution calculated is 0.12 to 0.17 L/kg.

Diclofenac enters the synovial fluid, where maximum concentrations are measured 2 to 4 hours after peak plasma values have been reached. The apparent half-life for elimination from the synovial fluid is 3 to 6 hours. Two hours after reaching peak plasma levels, concentrations of the active substance are already higher in the synovial fluid than in the plasma, and they remain higher for up to 12 hours.

Biotransformation/metabolism

Biotransformation of diclofenac takes place partly by glucuronidation of the intact molecule, but mainly by single and multiple hydroxylation and methoxylation, resulting in several phenolic metabolites (3'-hydroxy-, 4'-hydroxy-, 5-hydroxy-, 4',5-dihydroxy-, and 3'-hydroxy4'-methoxy-diclofenac), most of which are converted to glucuronide conjugates.

Two of these phenolic metabolites are biologically active, but to a much lesser extent than diclofenac.

Elimination

Total systemic clearance of diclofenac from plasma is 263 ± 56 mL/min (mean value $\pm$ SD). The terminal half-life in plasma is 1 to 2 hours. Four of the metabolites, including the two active ones, also have short plasma half-lives of 1 to 3 hours. One metabolite, 3'-hydroxy4'-methoxy-diclofenac, has a much longer plasma half-life. However, this metabolite is virtually inactive.

About 60% of the administered dose is excreted in the urine as the glucuronide conjugate of the intact molecule and as metabolites, most of which are also converted to glucuronide conjugates. Less than 1% is excreted as unchanged substance. The rest of the dose is eliminated as metabolites through the bile in the faeces.

Linearity/non-linearity

The amount absorbed is linearly related to the size of the dose.

Special populations

Geriatric patients

No relevant age-dependent differences in the drug's absorption, metabolism, or excretion have been observed.

Renal impairment

In patients suffering from renal impairment, no accumulation of the unchanged active substance can be inferred from the single-dose kinetics when applying the usual dosage schedule. At a creatinine clearance of less than 10 mL/min, the calculated steady-state plasma levels of the hydroxy metabolites are about 4 times higher than in normal subjects. However, the metabolites are ultimately cleared through the bile.

Hepatic impairment

In patients with chronic hepatitis or non-decompensated cirrhosis, the kinetics and metabolism of diclofenac are the same as in patients without liver disease.

5.3 Preclinical safety data

Cataflam is a well-established product.

Non-clinical safety data

Preclinical data from acute and repeated dose toxicity studies, as well as from genotoxicity, mutagenicity, and carcinogenicity studies with diclofenac revealed no specific hazard for humans at the intended therapeutic doses. For more information, see Pregnancy, lactation, females and males of reproductive potential.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Core: Magnesium stearate; povidone; silica colloidal anhydrous; sodium starch glycollate; maize starch; calcium phosphate.

of

Sugar-coat: Microcrystalline cellulose; polyethylene glycol 8000; red iron oxide (E172) and titanium dioxide (E171) (dispersed Anstead); povidone; talc; sucrose.

Polish: polyethylene glycol 8000; sucrose.

Imprint with printing ink brown for 25 mg and white for 50 mg.

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

24 months

6.4 Special precautions for storage

Store at room temperature at no more than 30°C. Must be protected from moisture, Store in original package in order to protect from heat and light. Must be kept out of the reach and sight of children.

6.5 Nature of contents of container <and special equipment for use, administration or implantation>

20,100 coated tablets packed in PVC /PE/PVDC blister pack

6.6 Special precautions for disposal <and other handling>

No special requirements

7. MARKETING AUTHORIZATION HOLDER AND MANUFACTURING SITE ADDRESSES

Novartis Pharma AG
Lichstrasse 35 4056 Basel, Switzerland
+41613241111

Manufacturing Site

Novartis Saglik, Gida ve Tarim Urunleri, Turkey,
Yenisehir Mahallesi Ihlara Vadisi Sokak No. 2 Pendik Intanbul TR 34912 Turkey

8. MARKETING AUTHORISATION NUMBER-

FDA/SD.233-111285

9. DATE OF FIRST AUTHORIZATION OR RE

30/11/2023

10. DATE OF REVISION OF THE TEXT

07/08/2025